- 1 Time-to-event estimation of birth year prevalence trends:
- 2 a method to enable investigating the etiology of
- 3 childhood disorders including autism
- 4 Alexander G. MacInnis^{1*}

- 6 ¹ Independent researcher, Mountain View, California, United States of America
- 7 * Corresponding author
- 8 Email: a.macinnis@alumni.stanford.edu (AGM)

Abstract

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

Measures of incidence are essential for investigating etiology. For congenital diseases and disorders of early childhood, birth year cohort prevalence serves the purpose of incidence. There is uncertainty and controversy regarding the birth prevalence trend of childhood disorders such as autism and intellectual disability because changing diagnostic factors can affect the rate and timing of diagnosis and confound the true prevalence trend. The etiology of many developmental disorders is unknown, and it is important to investigate. This paper presents a novel method, Time-to-Event Prevalence Estimation (TTEPE), to accurately estimate the time trend in birth prevalence of childhood disorders correctly adjusted for changing diagnostic factors. There is no known existing method that meets this need. TTEPE is based on established time-toevent (survival) analysis techniques. Input data are rates of initial diagnosis for each birth year cohort by age or, equivalently, diagnostic year. Diagnostic factors form diagnostic pressure, i.e., the probability of diagnosing cases, which is a function of diagnostic year. Changes in diagnostic criteria may also change the effective prevalence at known times. A discrete survival model predicts the rate of initial diagnoses as a function of birth year, diagnostic year, and age. Diagnosable symptoms may develop with age, affecting the age of diagnosis, so TTEPE incorporates eligibility for diagnosis. Parameter estimation forms a non-linear regression using generalpurpose optimization software. A simulation study validates the method and shows that it produces accurate estimates of the parameters describing the trends in birth prevalence and diagnostic pressure. The paper states the assumptions underlying the

analysis and explores optional additional analyses and potential deviations from assumptions. TTEPE is a robust method for estimating trends in true case birth prevalence controlled for diagnostic factors and changes in diagnostic criteria under certain specified assumptions.

Keywords

31

32

33

34

35

39

- 36 Birth year prevalence; birth year cohort; incidence; time-to-event; survival analysis;
- 37 diagnostic factors; diagnostic pressure; non-linear regression; autism; intellectual
- 38 disability; childhood disorders; developmental disorders

Introduction

40 In epidemiology, incidence - the rate of new cases - is a fundamentally important metric 41 for estimating causal associations of time-varying risk factors with rates of a disorder 42 [1,2]. Incidence is different from prevalence, which is the proportion of a defined 43 population with the disorder at a defined time. For some disorders including congenital 44 diseases and developmental disorders such as autism and intellectual disability, birth 45 year cohort prevalence is used instead of incidence [2,3] because disorder incidence is 46 indistinguishable from birth prevalence, and diagnosis may occur later if at all. 47 Sometimes "incidence" is used to mean the rate of incident diagnoses rather than true 48 incidence, which refers to a disorder. While this usage is understandable because 49 observations inherently represent diagnosis and identification, the difference can be

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Time-to-Event Prevalence Estimation

critically important when there is uncertainty about the rate and timing of diagnosing or identifying cases. Serious developmental disorders such as autism and intellectual disability are important topics of study because they cause a significant reduction in quality of life across the lifespan [4] for the individuals and their families, and they affect large numbers of people. Studies of time trends in birth year prevalence or incidence are subject to biases resulting from changes in diagnostic factors and diagnostic criteria [2]. Investigators can estimate incidence and birth prevalence directly from data on diagnoses. But concerns that diagnostic factors and diagnostic criteria may have affected the data can lead to a lack of confidence in the validity of direct estimates. Diagnostic factors are those that influence the probability of diagnosing or identifying cases. Examples include awareness, outreach efforts, screening, diagnostic practice, diagnostic criteria, social factors, policies, and financial incentives for diagnosis. Changes in diagnostic criteria can also have the additional effect of changing the effective birth prevalence by including or excluding as cases some portion of the population compared to prior criteria, with the changes occurring when the new criteria take effect. Consider, for example, this question. If reported birth prevalence increased over time, was this caused by changes in actual birth prevalence, the probability of diagnosing cases, diagnostic criteria affecting prevalence, or some combination of these factors? It

is challenging to disentangle these effects, and there is no known existing method capable of doing so correctly.

Literature Review

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

There are many studies on the prevalence of developmental disorders, yet very few of them directly address birth year prevalence trends and very few address methods of adjustment for diagnostic factors. The series of reports from the US Centers for Disease Control and Prevention's (CDC) Autism and Developmental Disabilities Monitoring Network (ADDM) [5-13] estimate the prevalence of autism among children who were eight years old at each even-numbered year 2000 through 2016. Each report describes the prevalence of a single year birth cohort, subject to rounding, born eight years before the respective study year. The set of reports represents the trend in birth year prevalence, but the reports describe the findings as simply "prevalence," and do not discuss birth year prevalence or similar names. The ADDM reports suggest that the observed increases in (birth year) prevalence may result from various factors, including changing composition of study sites and geographic coverage, improved awareness, and changes in diagnostic practice and availability of services. However, they do not suggest methods to quantify such effects or to adjust for them. Croen [14] examined birth year prevalence trends in autism and mental retardation in California for birth years 1987 to 1994. They concluded that the data and methods available were insufficient to determine how much of the observed increase reflected an increase in true birth prevalence. Hansen [15] recommends using the cumulative incidence of diagnoses of childhood psychiatric disorders for each 1-year birth cohort as a measure of risk. They

do not suggest an analytical method to estimate or adjust for the effects of diagnostic factors. Nevison [16] presents California Department of Developmental Services data showing a sharp rise in birth year prevalence of autism over several decades but does not discuss methods to adjust for the effects of diagnostic factors.

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Elsabbagh [17] states that investigating time trends in prevalence or incidence requires holding diagnostic factors such as case definition and case ascertainment "under strict control over time," but does not suggest a method for doing so. Campbell [18] reviews prevalence estimates and describes an ongoing controversy about them. They emphasize the distinction between prevalence and incidence but do not mention birth year prevalence. They summarized the CDC ADDM estimates and stated that one cannot infer incidence from the ADDM prevalence estimates. However, they did not mention that the ADDM estimates are birth year prevalence, which serves the purpose of incidence for childhood disorders. Campbell indicates that analyses should control for certain diagnostic factors, but they do not suggest a method for doing so. Baxter [4] examined prevalence and incidence but did not mention birth year prevalence and did not indicate whether their use of "incidence" refers to incident diagnoses or incidence of the disorder. Later sections of this paper show why the distinction is crucial. Baxter adjusted for covariates that they assumed introduced bias, including the use of dichotomous variables representing the most recent diagnostic criteria. Such variables inherently represent the time each set of criteria took effect. However, Schisterman [19] shows that controlling for variables on a causal path from the input (time, in this case) to

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

Time-to-Event Prevalence Estimation

the outcome (prevalence or incident diagnoses) constitutes inappropriate adjustment and biases the estimate of the primary effect (i.e., of time on prevalence or incident diagnoses) towards zero. Similarly, Rothman [2] states that controlling for intermediate variables typically causes a bias towards finding no effect. Keyes [20] used age-period-cohort analysis to attempt to disentangle the effects of birth year (cohort) from diagnostic year (period) and concluded that period effects best explain observed California data. They also argued that period effects represent diagnostic factors, without noting that birth year prevalence is inherently a cohort effect. Spiers [21], in a letter regarding Keyes, pointed out that the method used is extremely sensitive to the constraints specified and could as easily have concluded that period, i.e., diagnostic year, effects best explain the data. Spiers also disputed Keyes' interpretation of cohort effects. King [22] implicitly used an age-period-cohort analysis, assuming that period effects are dominant and controlling for birth year. There is extensive literature on the problems with using age-period-cohort analysis to separate the effects of birth year (cohort) from diagnostic year (period). Rodgers [23] states that a constraint of the type used in Keyes "in fact [it] is exquisitely precise and has effects that are multiplied so that even a slight inconsistency between the constraint and reality, or small measurement errors, can have very large effects on estimates." O'Brien [24], in a book devoted to this topic, states, regarding the relationships of age, period and cohort to the dependent variable, "There is no way to decide except by making an assumption about the relationship between these three variables." MacInnis [25] showed that

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

Time-to-Event Prevalence Estimation

diagnostic factors are represented by the years of first diagnoses, formulates the problem as one of separating birth year from diagnostic year, and shows that ageperiod-cohort approaches are not suitable for such analyses. In particular, implicit assumptions to make the model estimable cause the resulting estimates to conform to the assumptions, forming circular logic. Campbell [18] and McKenzie [26] both point out that various factors could potentially affect the rate of diagnoses without affecting the true case rate. Overview The primary aim of this work is to develop and specify a method to estimate birth prevalence trends, correctly adjusted for trends in the set of diagnostic factors and changes in diagnostic criteria. Armed with such a tool, researchers can quantify the effects of the set of variable causal factors separately from those of the set of diagnostic factors. Where covariates are available, investigators can estimate associations of birth prevalence with a variety of population characteristics that may be causal or explanatory. This paper presents a novel statistical method called time-to-event prevalence estimation (TTEPE). It uses time-to-event survival analysis to estimate the trend in true birth year prevalence, correctly adjusted for changes in the set of diagnostic factors and diagnostic criteria. It presents the derivation of the analytical method from first principles and states all the underlying assumptions. A simulation study shows that the method

effectively separates and quantifies the birth year trend and the trend in the effects of diagnostic factors, producing accurate estimates.

Method of time-to-event prevalence estimation

(TTEPE)


Background

Comparison of prevalence estimates across multiple studies generally is not suitable for informing tends in birth prevalence nor incidence [2]. Different prevalence estimates may use different mixes of birth years and ages, as well as numerous other possible differences between prevalence studies [27]. Many combinations of trends in birth prevalence and diagnostic factors could potentially explain observed prevalence trends. The Introduction section briefly describes the problems with age-period-cohort analyses. Age (A), diagnostic year (DY), and birth year (BY) are exactly collinear, DY = BY + A, subject to rounding, which leads to unidentified estimates when using a linear predictor. Another reason is that the age distribution of diagnoses can differ for different solutions of BY and DY, as shown below. It is challenging to estimate the age distribution correctly given the collinearity problem.

ambiguous. Here too, many combinations of trends in birth prevalence and diagnostic factors can produce similar trends in cumulative incidence.

Ambiguity in estimation

How should one interpret a dataset that produces any one of the cumulative incidence curves illustrated in Fig 1? The figure represents synthetic data; some real-world data may be similar. Observed data might produce a curve resembling any one of the curves in the figure. An exponential curve with a coefficient of 0.1 fits all three plotted lines reasonably well. Does this represent a true increase in birth prevalence with a coefficient of 0.1? Does it result from an exponential increase in the effects of diagnostic factors, with no increase in birth prevalence? Perhaps a combination of both? The three similar cumulative incidence curves represent quite different possible explanations. How to distinguish which one is correct?



192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

Time-to-Event Prevalence Estimation

Fig 1. Example of cumulative incidence under three models. β_P is the coefficient for birth prevalence; $\beta_{\rm H}$ is the coefficient for the effect of diagnostic factors. Red line with circles represents $\beta_P = 0.1$, $\beta_H = 0$; green line with squares represents $\beta_P = 0.08$, $\beta_H = 0.5$; blue line with crosses represents $\beta_P = 0$, $\beta_H = 0.134$. Fig 1 illustrates a hypothetical example of cumulative incidence to age ten over 20 consecutive cohorts. The legend lists the parameter value pairs for the three cases. β_P is the exponential coefficient of birth year prevalence, and β_h is the exponential coefficient of the effect of diagnostic factors by diagnostic year. The data generation process producing these data uses a survival process as detailed below. An Excel spreadsheet to generate all plots in this paper is available at OSF [28]. The variable hrepresents diagnostic pressure, the effect of diagnostic factors, which is equivalent to hazard, as explained in the section Significance of birth year and diagnostic year. While the three cumulative incidence curves appear similar, the age distributions of diagnoses are strikingly different, as Fig 2 shows. The remainder of this paper explains how modeling the age distribution of first diagnoses enables accurate and unambiguous

estimation of the coefficients for birth prevalence and diagnostic factors.




Fig 2. Distribution of diagnoses in the first and last cohorts under three models. β_P is the coefficient for birth prevalence; β_H is the coefficient for the effect of diagnostic factors. Red lines with circles represent $\beta_P = 0.1$, $\beta_H = 0$; green lines with squares represent $\beta_P = 0.08$, $\beta_H = 0.5$; blue lines with crosses represent $\beta_P = 0$, $\beta_H = 0.134$.

210

211

212

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

Time-to-Event Prevalence Estimation

If the disorder's complete cause is in place at birth, then the incidence of the disorder is indistinguishable from birth prevalence. In contrast, diagnosis occurs later, if at all. The incidence of diagnosis represents the combination of birth prevalence and delays and omissions in diagnoses. One might consider controlling for diagnostic factors over time, for example, via regression, but that is not sufficient to distinguish between alternative explanations. Diagnostic factors are a function of time, and birth year prevalence is also a function of time. As the Introduction states, controlling directly for diagnostic factors biases the estimates of the main effect, typically towards zero, citing Schisterman [19] and Rothman [2]. Schisterman recommends, "clearly stating a causal question to be addressed, depicting the possible data generating mechanisms using causal diagrams, and measuring indicated confounders." This paper directly addresses these issues. Significance of birth year and diagnostic year Diagnostic factors only affect the diagnosis of cases when those cases exhibit diagnosable symptoms, referred to as being eligible for diagnosis. Diagnostic pressure is the probability of diagnosing eligible undiagnosed cases, and it is an effect of the combination of all diagnostic factors. The Introduction lists examples.

Time-to-Event Prevalence Estimation

Diagnostic pressure is equivalent to the hazard h in time-to-event or survival analysis. For each case of the disorder, the information resulting from diagnostic pressure consists of the time of initial diagnosis, that is, the diagnostic year. Diagnostic pressure has no observable effect before the diagnosis of each case, and none after the initial diagnosis since TTEPE considers only initial diagnoses. Hence, the effect of diagnostic pressure on the input data is a function of diagnostic year.

The directed acyclic graph (DAG) in Fig 3 illustrates the causal paths from birth year, diagnostic year, and age to diagnosis. Birth year drives etiologic (causal) factors, which produce the disorder and its symptoms. Diagnostic criteria determine whether each individual's symptoms qualifies them as a case, and criteria may change at specific diagnostic years. Symptoms may vary with age. Diagnostic year drives diagnostic factors, which form diagnostic pressure. Diagnosable symptoms and diagnostic pressure together produce each initial diagnosis.




Fig 3. Directed Acyclic Graph Representing Year of Birth, Diagnostic Year and Age

Changes in diagnostic criteria can affect the threshold of symptoms that qualify case status. Criteria changes may change the proportion of the cohort classified as cases, i.e., the effective prevalence.

Development of the TTEPE method

The TTEPE method is based on the DAG of Fig 3 and modeling the age distribution of initial diagnoses. The method avoids the identification problem associated with age-period-cohort analysis, and it avoids the problem of inappropriate adjustment for diagnostic factors.

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

Time-to-Event Prevalence Estimation

TTEPE is particularly applicable to disorders where case status is established by birth or by a known age, and diagnosable symptoms are present by some consistent age. It is also useful where cases develop diagnosable symptoms gradually over a range of ages. Data sources suitable for TTEPE analysis provide rates of initial diagnoses by age or, equivalently, diagnostic year for each birth cohort. The rate is the count of initial diagnoses divided by the population of the cohort at the respective age. TTEPE relies on these principles: for each birth cohort, the number of cases at risk of initial diagnosis decreases as cases are diagnosed, and diagnostic year is the time when diagnostic factors affect the probability of diagnosing cases exhibiting diagnosable symptoms. First, consider the case where the diagnostic criteria do not change the effective prevalence over the interval of interest. The section Changes in criteria affecting prevalence examines the alternative. The principle of finding the simplest model that fits the data, sometimes called Occam's Razor, could lead to the conclusion that birth year effects best explain the observed birth year prevalence trends. However, the most parsimonious model is not always the

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

Time-to-Event Prevalence Estimation

best one [29]. Specifically, diagnostic pressure as a function of diagnostic year could potentially be an essential component for explaining observed diagnosis data. TTEPE is an extension of established time-to-event methods. TTEPE simultaneously estimates the birth prevalence and diagnostic pressure functions by fitting a model to the rate of initial diagnoses at each data point. It models the age distribution of rates of initial diagnoses via a survival process as a function of birth year, diagnostic year (birth year plus age), and eligibility. TTEPE introduces the concept of eligibility. A case is eligible for diagnosis if the individual has diagnosable symptoms and not eligible if the individual has not yet developed diagnosable symptoms. For each birth cohort, undiagnosed eligible individuals form the risk set of cases at risk of initial diagnosis. The size of the risk set is denoted R. At each age there is some probability of diagnosis of each case in the risk set. This probability is the diagnostic pressure h. At each age, newly diagnosed cases are removed from the risk set, and newly eligible cases are added to the risk set. For any given value of h, as R decreases or increases, the rate of initial diagnoses D changes accordingly. This process generates the modeled age distribution. The survival function S refers to cases that "survive" diagnosis at each age. If all cases were eligible from birth, S would equal R. More generally, however, some cases may initially be ineligible and become eligible as they age, so $R \leq S$. The prevalence P is the proportion

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

Time-to-Event Prevalence Estimation

of the population that are or become cases. The eligibility factor E is the eligible proportion of P, $0 \le E \le 1$. In contrast, in typical survival or time-to-event analysis, including Cox proportional hazards analysis [30], the initial size of the risk set is assumed to have a known value. for instance, an entire population or an entire sample. If the risk set R consisted of the entire population without subtracting diagnosed cases, the estimate $\hat{h}_t = D_t/R_t$ would be equivalent to the population-based rate of diagnoses D at time t. If the disorder is rare, it makes little difference whether the risk set is the entire population or the undiagnosed portion. Population-based rates of initial diagnoses D are observable while the other variables are not. Different values of diagnostic pressure h produce different values of D for a given value of prevalence *P*, as shown in the Illustrative example section. Time-to-event analysis model The analysis model enables estimation of the temporal trend of birth prevalence *P* over a range of cohorts, correctly adjusted for diagnostic pressure h. Both P and h can vary with time. P is a function of birth year, and h is a function of diagnostic year. Estimation

of P adjusted for h requires estimating the time-based parameters of both P and h in

the time-to-event model and specifying or estimating the eligibility function E.

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

Time-to-Event Prevalence Estimation

Let D_{BYA} be the population-based rate of incident diagnoses, where BY is birth year, and A is age. The model generates predicted values $\widehat{D_{BYA}}$. Modeling of proportions rather than counts accommodates changes in the population size of each cohort over time, e.g., due to in- and out-migration and deaths. Count values are useful for calculating p-values from chi-square goodness-of-fit measurements. Alternatively, the analysis could model counts directly. Let h_{DY} be the diagnostic pressure at diagnostic year DY. DY = BY + A, subject to rounding, so h_{DY} is equivalent to $h_{BY,A}$. Let P_{BY} be the case prevalence of birth year cohort BY. Let $R_{BY,A}$ be the discrete risk set function of the population proportion of eligible cases at risk of initial diagnosis at age A for birth year BY. TTEPE uses R rather than a discrete survival function S to accommodate eligibility changing with age. Let E_A be the discrete eligibility function, the proportion of cases that are eligible at age A, bounded by $0 \le E \le 1$. At each age $A \ge 1$, $P \times (E_A - E_{A-1})$ is the incremental portion of prevalent cases added to R due to changes in eligibility. For simplicity, assume E_A increases monotonically, i.e., non-decreasing, meaning that cases do not lose eligibility before diagnosis. Kalbfleisch [31] gives background on general time-to-event theory and equations. Consider three scenarios, differing by the characteristics of E_A . Here we write h_{DY} as $h_{BY,A}$ to clarify the effect of A in DY = BY + A.

Scenario: constant $E_A = 1$. All cases are eligible from birth, so $E_A = 1$ for all values of A.

346 This scenario is equivalent to standard time-to-event models that do not consider

347 eligibility. For
$$A \ge 1$$
, $E_A - E_{A-1} = 0$. For the first year of age, $A = 0$, $R_{BY,0} = P_{BY}E_0 = P_{BY}$

348 and
$$D_{BY,0} = R_{BY,0}h_{BY,0} = P_{BY}h_{BY,0}$$
.

349 For
$$A = 1$$
, $R_{BY,1} = P_{BY} - D_{BY,0} = P_{BY} - P_{BY} h_{BY,0} = P_{BY} (1 - h_{BY,0})$ and

350
$$D_{BY,1} = R_{BY,1}h_{BY,1} = P_{BY}(1 - h_{BY,0})h_{BY,1}$$
.

351 For
$$A = 2$$
, $R_{BY,2} = R_{BY,1} - D_{BY,1} = P_{BY}(1 - h_{BY,0}) - P_{BY}(1 - h_{BY,0})h_{BY,1} =$

352
$$P_{BY}(1-h_{BY,0})(1-h_{BY,1})$$
 and $D_{BY,2}=R_{BY,2}h_{BY,2}=P_{BY}(1-h_{BY,0})(1-H_{BY,1})h_{BY,2}$.

353 Similarly, for A = 3,

354
$$R_{BY,3} = P_{BY}(1 - h_{BY,0})(1 - h_{BY,1})(1 - h_{BY,2})$$
 and

355
$$D_{BY,3} = P_{BY}(1 - h_{BY,0})(1 - h_{BY,1})(1 - h_{BY,2})h_{BY,3}$$
.

357 Generally, for $A \ge 1$,

358
$$R_{BY,A} = P_{BY} \prod_{a=0}^{A-1} (1 - h_{BY,a})$$

359 and

361

356

344

360
$$D_{BY,A} = P_{BY} \prod_{a=0}^{A-1} (1 - h_{BY,a}) h_{BY,A}$$
 (1)

In all three scenarios in this paper, the survival function is:

$$S_{BY,A} = P_{BY} - \sum_{a=0}^{A-1} D_{BY,a}$$
 (2)

- The summation term is the cumulative incidence of initial diagnoses through age A-1.
- Scenario: Increasing E_A . $E_0 < 1$ and E_A increases monotonically with E_A . For $E_A = 0$,
- 367 $R_{BY,0} = E_0 P_{BY}$ and $D_{BY,0} = E_0 P_{BY} h_{BY,0}$. For each $A \ge 1$, $R_{BY,A} = R_{BY,A-1} D_{BY,A-1} +$
- 368 $(E_A E_{A-1})P_{BY}$. The incremental increase of E_A causes an incremental increase in $R_{BY,A}$.
- 369 Then,

365

375

377

379

381

370
$$D_{BY,A} = R_{BY,A}h_{BY,A} = (R_{BY,A-1} - D_{BY,A-1})h_{BY,A} + (E_A - E_{A-1})P_{BY}h_{BY,A}$$
(3)

- 371 Equation (3) can be useful as a procedural definition. We can write equivalent
- 372 expressions for $R_{BY,A}$ and $D_{BY,A}$ as sums of expressions similar to equation (1), where
- 373 each summed expression describes the portion of P_{BY} that becomes eligible at each
- 374 age according to E_A . For $A \ge 1$,

376
$$R_{BY,A} = \sum_{a=0}^{A-1} (E_a - E_{a-1}) P_{BY} \prod_{b=a}^{A-1} (1 - h_{BY,b})$$

378
$$D_{BY,A} = \sum_{a=0}^{A-1} (E_a - E_{a-1}) P_{BY} \prod_{b=a}^{A-1} (1 - h_{BY,b}) h_{BY,A}$$
 (4)

where E_{-1} is defined to be 0. E_A can be defined parametrically or non-parametrically.

Scenario: Plateau E_A . E_A increases from $E_0 < 1$ and plateaus at $E_A = 1$ for $A \ge AE$,

where AE is the age of complete eligibility, AE < M, and M is the maximum age

included in the analysis. Equation (3) applies, noting that for A > AE, $(E_A - E_{A-1}) = 0$.

Equivalently, combine equation (2) with the fact that $E_{AE}=1$ to obtain $R_{AE}=S_{AE}=P_{BY}-1$

 $\sum_{a=0}^{AE-1} D_{BY,a}$, so

387
$$D_{BY,AE} = R_{BY,AE} h_{BY,AE} = S_{BY,AE} h_{BY,AE} = (P_{BY} - \sum_{a=0}^{AE-1} D_{BY,a}) h_{BY,AE}$$
 (5)

388 and for A > AE,

389
$$R_{BY,A} = S_{BY,A} = (P_{BY} - \sum_{a=0}^{AE-1} D_{BY,a}) \prod_{b=AE}^{A-1} (1 - h_{BY,b})$$

391
$$D_{BY,A} = (P_{BY} - \sum_{a=0}^{AE-1} D_{BY,a}) \prod_{b=AE}^{A-1} (1 - h_{BY,b}) h_{BY,A}$$
 (6)

The scenario of increasing E_A is a general formulation and may not be needed in practice. The plateau E_A scenario may be appropriate when external information, such as the definition of the disorder, indicates the value of AE, or when investigators specify AE based on estimates of E_A found using equation (4). Equations (5) and (6) do not model E_A nor $D_{BY,A}$ for A < AE. Rather, they use the empirical values of $D_{BY,A}$ for A < AE.

Prevalence, cumulative incidence and censoring

The case prevalence in each cohort is the cumulative incidence of initial diagnoses through the last age of follow-up plus the censored portion. This assumes that any difference in competing risks between cases and non-cases in the age range analyzed is small enough to be ignored. This assumption is consistent with Hansen [15]. If the rate of deaths of cases before initial diagnosis exceeds that of the entire population of the cohort at the same ages, that excess would constitute a competing risk and would reduce the estimated prevalence accordingly.

In all three scenarios of E_A , we can express P as a function of S and the cumulative incidence $CI = \sum_{a=0}^{A-1} D_{BY,a}$ for A > 0, by rearranging equation (2) as $P = S_A + CI_{A-1}$. Assuming that eligibility at the last age of follow-up $E_M = 1$, $S_M = R_M$. Then, $P = R_M + CI_{M-1}$ and $D_M = R_M h_M$. The censored proportion is $S_{M+1} = S_M - D_M$, which is equivalent to $S_{M+1} = R_M - R_M h_M = R_M (1 - h_M)$. After estimating the model parameters, the estimated censored proportion is $\widehat{S_{M+1}} = \widehat{R_M} (1 - \widehat{h_M})$.

Illustrative example

Fig 4 illustrates an example according to the plateau E_A scenario showing the relationships between prevalence, diagnosis rates, the survival function, and cumulative incidence CI with two different values of diagnostic pressure h = 0.1 and h = 0.25 and prevalence P = 0.01. In this example, E = 1 for $A \ge AE = 3$ and h takes on one of two constant values. The value of h determines the shapes of these functions vs. age. This

example shows constant values of h purely for clarity, not as an assumption nor a

limitation of TTEPE.

420

421

423

424

425

426

427

428

429




Fig 4. Example of a survival process for two values of diagnostic pressure *h*.

The green lines S denote survival, the blue lines D denote the rate of diagnoses, and the red lines CI denote cumulative incidence. The solid lines represent h=0.1, and the dotted lines represent h=0.25.

As cases are diagnosed, S decreases and CI increases. R is not shown; R = S for $A \ge AE = 3$. Only D is observable.

Assumptions

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

Several baseline assumptions enable TTEPE analysis. Some assumptions may be relaxed, as discussed below. 1. The eligibility function E_A under consistent diagnostic criteria is consistent across cohorts. 2. The diagnostic pressure applies equally to all eligible undiagnosed cases at any given diagnostic year. 3. The case prevalence under consistent diagnostic criteria within each cohort is constant over the range of ages included in the analysis. 4. Case status is binary according to the applicable diagnostic criteria. 5. The discrete-time interval (e.g., one year) is small enough that the error introduced by treating the variable values as constant within each interval is negligible. 6. No false positives. 7. Data represent truly initial diagnoses. 8. Any difference in competing risks between cases and non-cases in the age range analyzed is small enough to be ignored. The assumption of a consistent eligibility function means that cases develop diagnosable symptoms as a function of age, and that function is the same for all cohorts

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

Time-to-Event Prevalence Estimation

under consistent diagnostic criteria. The section Changes in criteria affecting prevalence discusses a separate effect that might make the eligibility function appear inconsistent. **Estimating parameters** TTEPE performs a non-linear regression that estimates the parameters of a model of $D_{BY,A}$ using general-purpose optimization software. The model is based on equations (1) through (6) selected based on the eligibility scenario. The model produces estimates $\widehat{D_{BY,A}}$ from the parameters and independent variables, and the software finds the parameter values that minimize a cost function $cost(D, \widehat{D})$. One suitable implementation of optimization software in the Python language is the curve fit() function in the SciPy package (scipy.optimize.curve_fit in SciPy v1.5.2). Its cost function is $(D - \widehat{D})^2$, so it minimizes the sum of squared errors. Python software to perform this regression and the simulations described below is available at OSF [28]. Investigators should choose which model equation to use based on knowledge or estimates of the eligibility function E_A . The constant E_A scenario and equation (1)

estimates of the eligibility function E_A . The constant E_A scenario and equation (1) assume that all cases are eligible from birth, which may not be valid for some disorders. The validity of the assumption that all cases are eligible by a known age AE, i.e., the plateau E_A scenario and equation (6), may be supported by either external evidence, e.g., the definition of the disorder, or estimation of E_A . The least restrictive approach of the increasing E_A scenario uses equation (4) to estimate E_A . Non-parametric estimates $\widehat{E_A}$ can inform a choice of a parametric form of E_A . The value of E_A at the maximum age studied E_A should be set to 1 to ensure the estimates are identifiable. If $E_A = 1$ for all $E_A = 1$

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

Time-to-Event Prevalence Estimation

AE, that fact and the value of AE should be apparent from estimates $\widehat{E_A}$, and the plateau E_A scenario applies. Investigators should choose forms of P_{BY} and $h_{BY,A}$ appropriate to the dataset. Linear, first-order exponential, second-order exponential or non-parametric models may be appropriate. Graphical and numeric model fit combined with degrees of freedom can guide the optimum choice of a well-fitting parsimonious model. TTEPE preferably estimates P and h simultaneously over a series of cohorts, utilizing data points from all cohorts, thereby enabling well-powered estimation and flexible model specification. Alternatively, under some conditions, it may be possible to estimate h in a single cohort and estimate P based on \hat{h} . Suppose the population proportion of cases represented in the data is unknown for all cohorts. In that case, estimates of the absolute prevalence, or the intercept, may be underestimated by an unknown scale factor. If that proportion is known for at least one cohort, we can use it to calibrate the intercept. Proportional changes in prevalence between cohorts are unaffected by underestimation of the intercept. If the population proportion of cases included in the sample changes over time, that change reflects changing diagnostic factors, and the estimated parameters of h automatically represent such changes.

Changes in criteria affecting prevalence

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

512

513

514

Changes in diagnostic criteria could potentially affect rates of initial diagnoses by changing the effective prevalence. This mechanism is distinct from diagnostic pressure. Changes in criteria may change the effective prevalence within a cohort, without affecting symptoms or etiology, by including or excluding as cases some portion of the cohort population compared to prior criteria. A criteria change may change the effective prevalence of the entirety of any cohort where the birth year is greater than or equal to the year the change took effect. For birth years before the year of criteria change, a change in criteria that changes the effective prevalence causes an increase or decrease in the size of the risk set R starting at the diagnostic year the change took effect. Generally, diagnostic criteria should be given in published documents, such that changes in criteria correspond to effective dates of new or revised specifications. Let $\{CF_{cv}\}$ be the set of criteria factors that induce a multiplicative effect on effective prevalence due to criteria changes that occurred at criteria years $\{cv\}$ after the first DY included in the study. P_{BY} is the prevalence of cohort BY before the effect of any of

$$EP_{BY,A} = P_{BY} \prod_{cy \le (BY+A)} CF_{cy} \tag{7}$$

 $\{CF_{cv}\}$. For each cohort BY, the effective prevalence $EP_{BY,A}$ at age A is

where CF_0 , the value in effect before the first DY in the study, equals 1. The combination of P_{BY} and the effects of all $\{CF_{cy}|cy\leq BY+A\}$ determines the final effective prevalence of each cohort.

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

Time-to-Event Prevalence Estimation

For a given BY and increasing A, BY + A crossing any cy causes a step-change in the effective prevalence EP. Using a general formulation of eligibility E_A , per the increasing E_A scenario and equation (3), and for clarity substituting BY + A for DY, we obtain the following. For A=0, $R_{BY,0}=E_0EP_{BY,0}$ and $D_{BY,0}=E_0EP_{BY,0}h_{BY,0}$. For $A\geq 1$, $R_{BY,A} = R_{BY,A-1} - D_{BY,A-1} + E_A(EP_{BY,A} - EP_{BY,A-1}) + (E_A - E_{A-1})EP_{BY,A}$ and $D_{BY,A} = [R_{BY,A-1} - D_{BY,A-1} + E_A(EP_{BY,A} - EP_{BY,A-1}) + (E_A - E_{A-1})EP_{BY,A}]h_{DY}$ (8) The term $EP_{BY,A} - EP_{BY,A-1}$ represents the change in the effective prevalence EP when BY + A crosses one of $\{cy\}$. As each CF_{cy} takes effect at cy = DY = BY + A, the newly effective CF_{CV} changes $EP_{BY,A}$ and R in all BY cohorts where cy corresponds to an age A in the range of ages studied. These changes in *R* affect the rates of initial diagnoses *D*. For cohorts born after cy, CF_{cv} applies to all ages. The parameters of P_{BY} quantify the birth year prevalence controlled for diagnostic criteria changes, which are represented by $\{CF_{CV}\}$. In other words, P_{BV} is the cohort prevalence that would have occurred if the initial criteria had been applied at all diagnostic years included in the study. To estimate the parameters, use a software model of equation (8) with optimization software, as described in the previous section.

Potential violations of assumptions

Suppose a dataset represents a non-homogeneous set of cases with different effective values of diagnostic pressure h applying to different unidentified subgroups at the same DY. That would violate the assumption that the diagnostic pressure applies equally to all eligible undiagnosed cases at any given DY. Cases may have differing degrees of symptom severity, and more severe symptoms may result in earlier diagnosis [32], implying greater diagnostic pressure. Fig 5 illustrates this situation. The figure illustrates constant values of h purely for clarity, not as an assumption nor a limitation. If data represent unidentified subgroups with differential diagnostic pressure, the distribution of diagnoses is a sum of distributions with different values of h. Such a sum of distributions with different values of h may impair fit with a model that assumes homogeneous h. For data where E = 1 for $A \ge AE$ (plateau E_A), adjusting the assumed value of AE used in estimation, called AE^* , may mitigate such errors, as shown in the Simulation study section. Stratified estimation using subgroup data, if available, can avoid the issue of unidentified non-homogenous subgroups.




Fig 5. Example where observed diagnosis rates represent two unidentified subgroups with different values of diagnostic pressure. The red and green lines represent rates of diagnosis of the two subgroups. The solid black line shows the aggregate diagnosis rates. The dotted line shows the exponential fit to the aggregate diagnosis rates. The age of eligibility AE = 3 in this example.

Any imbalance of case prevalence between in-migration and out-migration to and from the region defining the population over the study period would violate the assumption of constant prevalence within each cohort.

If some in-migrating cases were diagnosed before in-migration and their subsequent rediagnoses in the study region were labeled as initial diagnoses, that would violate the

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

Time-to-Event Prevalence Estimation

assumption of truly first diagnoses. Such an effect would be most evident at greater ages after the diagnosis of most cases. Bounding the maximum age studied M to a modest value, sufficient to capture most initial diagnoses, can minimize any resulting bias. Apart from subgroups with non-homogeneous h, it is theoretically possible for h to have different effective values for cases of different ages with the same symptom severity at the same DY. Such an effect would represent an age bias in diagnostic pressure, independent of symptom severity. If there is a reason to suspect such an age bias, investigators can add an age parameter to h in the model and estimate its parameters. For datasets where diagnosis follows best practices using gold-standard criteria, the lack of false positives may be a fair assumption. It would be difficult to discover any false positives in that case. Where diagnosis uses a less precise process, some false positives might occur. For example, diagnosticians might tend to produce a positive diagnosis of individuals who do not meet formal diagnostic criteria, perhaps under pressure from the patient or parents, or to facilitate services for the individual. In scenarios where the rate of false positives is significant, the age distribution relative to the rates of true diagnoses may be important. If false positives are uniformly distributed over the age range studied, they would cause a constant additive offset to the rates of diagnoses. True case diagnoses should be more common at younger ages, and less common as the risk pool is depleted, so false positives may be relatively more evident

at older ages. If false positives are more common at older ages, their effect may be even more obvious.

Model fit

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

To ensure robust conclusions, investigators should test the model fit to ascertain both model correctness and parameter estimation accuracy. The model fits well if summary measures of the error are small and individual point errors are unsystematic and small [33]. One can examine the fit both graphically and numerically. Plots of D_{BYA} vs. $\widehat{D_{BYA}}$ at all ages for individual cohorts can illuminate any issues with fit, which might occur at only some cohorts or ages. Visualization of the model vs. data can expose aspects of the data that might not fit well in a model with few parameters, possibly suggesting a higher-order model or semi-parametric specifications. If the model uses an assumed age of complete eligibility AE^* that differs from the true value of AE represented by the data, model fit may be impaired, particularly if $AE^* < AE$. As the Simulation study section shows, setting $AE^* < AE$ can result in estimation errors. Setting $AE^* > AE$ tends not to impair model fit and may improve it in the case of nonhomogeneous subgroups; see Fig 5. The presence of non-homogeneous subgroups may be evident from examining model fit. The chi-square test statistic, applied to the overall model, individual cohorts, and single ages across cohorts, is a numerical approach to assess absolute model fit. The p-value

associated with the chi-square statistic utilizes observed and expected count values, not proportions. The p-value incorporates the effect of the number of parameters in the model via the degrees of freedom.

Simulation study

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

We tested the TTEPE method via a simulation study where we know the ground truth of all parameters, following the recommendations in Morris [34]. There are six pairs of values of β_h and β_P , each ranging from 0 to 0.1 in steps of 0.02, and each pair sums to 0.1. In one parameter set, the prevalence increases as $e^{0.1 \times BY}$ and diagnostic pressure is constant; in another parameter set, the prevalence is constant and diagnostic pressure increases as $e^{0.1 \times DY}$; and the other four parameter sets represent various rates of change of both variables. In all cases, P = 0.01 at the final BY, h = 0.25 at the final DY, AE = 3, M = 10, and there are 20 successive cohorts. These simulations assume the investigators know the correct value $AE^* = 3$ from either knowledge of the disorder or estimation of E_A . The study synthesized each data model as real-valued proportions without sampling and with binomial random sample generation of incident diagnoses. For sampling, the population of each cohort is a constant 500,000. Monte Carlo simulation of parameter estimation bias and model standard error (SE) used 1000 iterations of random data generation for each set of parameters. Parameter estimation is as described above, implemented using the Python SciPy curve_fit() function.

Table 1 shows results using real-valued proportions without sampling, isolating the estimation process from random sampling variations. It shows the bias in estimating each of the four model parameters for each of the six combinations of β_h and β_P . The biases are minimal; the greatest bias magnitude in $\widehat{\beta_P}$ occurs with $\beta_P = 0$ and $\beta_h = 0.1$ and is on the order of 10^{-10} .

Table 1. Simulation results of parameter optimization using real-valued proportions with no sampling.

True Parameters		Bias \widehat{P}	Bias $\widehat{oldsymbol{eta}_P}$	Bias \hat{h}	Bias $\widehat{eta_h}$
		at final <i>BY</i>		at final <i>DY</i>	
$oldsymbol{eta_{ ext{P}}}$	$oldsymbol{eta_{ m h}}$				
0.1	0	5.9E-12	8.9E-11	-5.5E-10	-1.8E-10
0.08	0.02	0	0	-2.8E-17	-1.4E-17
0.06	0.04	-1.7E-18	0	1.1E-16	1.4E-17
0.04	0.06	3.5E-18	1.4E-17	-5.6E-17	-6.9E-18
0.02	0.08	0	3.5E-18	5.6E-17	-1.4E-17
0	0.1	-4.7E-11	-6.6E-10	2.2E-9	7.7E-10

P= 0.01 at the final BY, h =0.25 at the final DY, AE^* =AE=3, M= 10, and there are 20 successive cohorts.

 β_P , β_h are coefficients for prevalence and hazard, respectively.

P, prevalence; BY, birth year; DY, diagnostic year.

Time-to-Event Prevalence Estimation

Table 2 gives results from Monte Carlo analysis of the same parameter sets where the data use binomial sampling. It shows the bias and model SE of each parameter for each parameter set. The bias of the primary parameter $\widehat{\beta}_P$ remains small, on the order of 10^{-5} or 10^{-6} . The SE is relevant when considering sampling, and it shows the effect of sampling compared to Table 1.

Table 2. Simulation results of parameter optimization using Monte Carlo with binomial sampling, 1000 iterations.

•	True	\widehat{P} at	final BY		$\widehat{oldsymbol{eta}_P}$	\widehat{h} at f	inal DY	Î	$\widehat{\beta_h}$
Para	ameters	3							
$oldsymbol{eta}_{ ext{P}}$	$oldsymbol{eta_h}$	Bias	SE	Bias	SE	Bias	SE	Bias	SE
0.1	0	-2.0E-6	1.0E-4	-2.0E-5	0.0013	3.3E-5	0.0070	-5.4E-6	0.00191
0.08	0.02	-2.6E-6	1.1E-4	-3.2E-5	0.0012	1.5E-4	0.0072	4.4E-5	0.00191
0.06	0.04	7.8E-6	1.2E-4	2.7E-5	0.0013	-4.4E-4	0.0079	-1.2E-4	0.00207
0.04	0.06	6.5E-5	0.0015	6.5E-5	0.0015	-5.8E-4	0.0085	-1.6E-4	0.00224
0.02	0.08	-2.0E-6	1.6E-4	-9.8E-6	0.0016	4.4E-4	0.0086	9.4E-5	0.00227
0	0.1	4.5E-6	1.8E-4	7.1E-6	0.0017	2.0E-4	0.0094	2.7E-5	0.00234

Population of each cohort = 500,000. P=0.01 at the final BY, h=0.25 at the final

DY, $AE^* = AE = 3$, M = 10, and there are 20 successive cohorts.

 β_{P} , β_{h} are coefficients for prevalence and hazard, respectively.

P, prevalence; BY, birth year; DY, diagnostic year.

Time-to-Event Prevalence Estimation

Table 3 gives results where estimation uses an assumed value AE^* that, in some cases, does not match the true value of AE = 3 represented by the data. Synthesis uses one homogenous group with consistent h at each value of DY. Estimation using $AE^* = 2$ results in substantial estimation errors and model misfit that is obvious from plots of data vs. model (not shown). Estimation using $AE^* = 3$, $AE^* = 4$, or $AE^* = 5$ produces accurate results, with slightly more error where $AE^* = 5$. Plots show that the model fits well in all three cases (not shown). The choice of AE^* is not critical as long as $AE^* \ge AE$. These data use real-valued proportions to avoid confusing model mismatch with sampling effects.

Table 3. Comparison of the effect of the choice of assumed AE^* vs. true value of AE=3, with one homogeneous group of cases.

AE* used in	Bias \widehat{P} at	Bias $\widehat{oldsymbol{eta}_P}$	Bias \widehat{h}	Bias $\widehat{oldsymbol{eta}_h}$
estimation	final BY		at final DY	
2	0.002	-0.019	-0.0096	0.036
3	5.9E-12	8.9E-11	-5.5E-10	-1.8E-10
4	-4.4E-12	-6.6E-11	4.8E-10	1.64E-10
5	1.5E-11	2.2E-10	-1.85E-9	-7.18E-10

AE, age of complete eligibility. True values: $\beta_P = 0.1$, $\beta_h = 0$, P = 0.01 at the final BY, h = 0.25 at the final DY, AE = 3. Maximum age M = 10. 20 successive cohorts. Diagnostic pressure is consistent across cases at each DY. Simulation uses real values, no sampling.

Table 4 shows results with an intentional mismatch between estimation assuming one homogeneous group and data representing two subgroups with different values of h, illustrated in Fig 5. Note the visible error of the exponential fit to the data at age = 3 and a good fit for age > 3. In this synthetic dataset, the two subgroups are of equal size, and the true value of h in one group is twice that of the other. This information is not known to the estimation, and the data do not indicate subgroup size nor membership. In the worst case, estimation uses $AE^* = AE = 3$, and the $\widehat{\beta_P}$ bias is 0.001, which is 1% of the actual value of 0.1. This error is due to the subgroups having different hazards, which

are not accounted for in the estimation. When using $AE^* = 4$ or $AE^* = 5$, the $\widehat{\beta_P}$ bias becomes 6×10^{-4} or less, and model fit is improved (not shown).

Table 4. Comparison of the effect of the choice of assumed AE^* vs. true value of AE = 3, with two unidentified subgroups with different hazards, mismatched to analysis.

AE* used in	Bias \widehat{P} at	Bias $\widehat{oldsymbol{eta}_P}$	Bias \widehat{h}	Bias $\widehat{oldsymbol{eta}_h}$
estimation	final <i>BY</i>		at final <i>DY</i>	
3	-4.3E-4	0.001	0.0018	-0.002
4	-3.8E-4	6.1E-4	-0.004	-0.0016
5	-3.3E-4	3.5E-4	-0.0097	-0.0011

AE, age of complete eligibility. True values: $\beta_P = 0.1$, $\beta_h = 0$, P = 0.01 at the final BY, h = 0.25 at the final DY, AE = 3. Two equal-sized groups of cases where the diagnostic pressure h of one group is twice that of the other, while the estimation assumes one homogeneous group. Maximum age M = 10. 20 successive cohorts. Simulation uses real values, no sampling.

Discussion

Readers may suspect that the estimates are unidentified, i.e., not unique, due to possible interaction between age, diagnostic year, and birth year, such that estimates may be biased even if the model fit is excellent. While that concern is appropriate for analytical methods that assume an age distribution, ignore it, or estimate it

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

Time-to-Event Prevalence Estimation

inappropriately, including age-period-cohort methods, TTEPE avoids that problem and produces uniquely identified estimates. TTEPE models the age distribution of initial diagnoses as a non-linear function of birth year, diagnostic year, and other variables. Keep in mind that the eligibility function E_A is different from the age distribution of diagnoses; E_A is an attribute of the disorder under study. This paper states the assumptions that underlie TTEPE analysis. The DAG of Fig 3 illustrates the assumed causal paths from birth year, diagnostic year, and age, including the set of time-varying diagnostic factors and the effect of changes in criteria on effective prevalence. The DAG and associated analysis appear to cover all plausible mechanisms to explain observed trends in rates of initial diagnoses. TTEPE provides accurate estimates of prevalence parameters with a strong power to detect small differences. The Monte Carlo simulation study in Table 2 shows a magnitude of bias of the prevalence coefficient $\widehat{\beta}_P$ not exceeding 6.5×10^{-5} or 0.0065%per year. The model SE of $\widehat{\beta_P}$ ranges from 0.0012 to 0.0017, where the true β_P ranges from 0 to 0.1. Using the largest observed SE and $1.96 \times SE$ as a threshold for 95% confidence intervals, the method can detect differences in β_P of 0.0033, i.e., 0.33% per year. Investigators can expect similar performance for real-world datasets that meet the baseline assumptions and have characteristics comparable to the simulated data. The population size and prevalence affect the SE. Note that in the simulation study, there

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

Time-to-Event Prevalence Estimation

are 20 cohorts and 11 ages (0 through 10), so there are 220 data points. Each data point is an independent binomial random sample. The analysis estimates four parameters that define the curves that fit the data. The large number of independent data points and the small number of model parameters help to produce the small bias and model SE. If the population of each cohort or the prevalence was substantially smaller, or if the number of parameters was greater, we would expect the bias and SE to be larger. These could occur with small geographic regions, very rare disorders, or higher-order or semi-parametric models, respectively. TTEPE is useful for answering some important questions, such as the actual trend in case prevalence over multiple birth cohorts of disorders such as autism and intellectual disability, as described in Elsabbagh [17] and McKenzie [26] respectively. Accurate trend estimates can inform investigation into etiology. Where datasets include appropriate covariates, stratified analysis can estimate the relationships between various population characteristics and trends in true case prevalence and diagnostic factors. Example covariates include sex, race, ethnicity, socio-economic status, geographic region, parental education, environmental exposure, genetic profile, and other potential factors of interest. It may be feasible to extend TTEPE to disorders where the time scale starts at some event other than birth. For example, the time origin might be the time of completion of a sufficient cause, and various outcomes may serve as events of interest. It is important

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

Time-to-Event Prevalence Estimation

to ensure that the eligibility function with respect to the time origin is consistent across cohorts. Investigators may utilize domain knowledge to inform specialized analyses. For example, they may incorporate knowledge of mortality rates and standardized mortality ratios, rates of recovery from the condition before diagnosis, or the characteristics of migration in and out of the study region. **Acknowledgments** The author thanks Dr. Lu Tian for his expert advice on survival analysis methods; Dr. Lorene Nelson and Dr. Kristin Sainani for guidance on my thesis which was the genesis of this project and for comments on this paper; Dr. Michael Sigman and Dr. Larry Tang for their thoughtful reviews of the paper; and the Stanford Biomedical Data Science team for their project reviews and insightful comments. References 1. Szklo M, Nieto FJ. Epidemiology Beyond the Basics. 1st ed. Burlington (MA): Jones & Bartlett; 2014. 2. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia: Wolters Kluwer; 2008.

3. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, 756 757 regional, and national incidence, prevalence, and years lived with disability for 354 758 diseases and injuries for 195 countries and territories, 1990-2017: a systematic 759 analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858. 760 Suppl 1. 761 4. Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The 762 epidemiology and global burden of autism spectrum disorders. Psychol Med. 763 2015;45(3):601–613. 764 5. Centers for Disease Control. Prevalence of Autism Spectrum Disorders — Autism and Developmental Disabilities Monitoring Network, Six Sites, United States, 2000. 765 766 MMWR Surveillance Summaries. 2007; 56(SS01);1-11. Available from: 767 https://www.cdc.gov/mmwr/index.html. 768 6. Centers for Disease Control. Prevalence of Autism Spectrum Disorders — Autism 769 and Developmental Disabilities Monitoring Network, Six Sites, United States, 2002. MMWR Surveillance Summaries. 2007; 56(SS01);12-28. 770 771 7. Centers for Disease Control. Brief Update: Prevalence of Autism Spectrum 772 Disorders — Autism and Developmental Disabilities Monitoring Network, United 773 States, 2004. MMWR Surveillance Summaries. 2009; 58(SS-10);21-24. 774 8. Centers for Disease Control. Prevalence of Autism Spectrum Disorders — Autism 775 and Developmental Disabilities Monitoring Network, United States, 2006. MMWR

Surveillance Summaries. 2009; 58(SS-10);1-20.

776

- 9. Centers for Disease Control. Prevalence of Autism Spectrum Disorders Autism 777 778 and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008. 779 MMWR Surveillance Summaries. 2012;61(SS-3):1-19. 780 10. Centers for Disease Control. Prevalence of Autism Spectrum Disorders — Autism 781 and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2010. 782 MMWR Surveillance Summaries. 2014;63(SS-2):1-21. 783 11. Centers for Disease Control. Prevalence of Autism Spectrum Disorders — Autism 784 and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. 785 MMWR Surveillance Summaries. 2018;65(13):1-23. 786 12. Centers for Disease Control. Prevalence of Autism Spectrum Disorders — Autism 787 and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. 788 MMWR Surveillance Summaries. 2018;67(6):1-23. 789 13. Centers for Disease Control. Prevalence of Autism Spectrum Disorders — Autism 790 and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016. 791 MMWR Surveillance Summaries. 2020;69(4):1-12.
- 14. Croen LA, Grether JK, Hoogstrate J, Selvin S. The Changing Prevalence of Autism
 in California. J Autism Dev Disord. 2002;32(3):207-215.
- 15. Hansen SN, Overgaard M, Andersen PK, Parner ET. Estimating a population
 cumulative incidence under calendar time trends. BMC Med Res Methodol.
 2017;17:7.

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

Time-to-Event Prevalence Estimation

16. Nevison C, Blaxill M, Zahorodny W. California Autism Prevalence Trends from 1931 to 2014 and Comparison to National ASD data from IDEA and ADDM. J Autism Dev Disord. 2018; (doi.org/10.1007/s10803-018-3670-2). Suppl S1. 17. Elsabbagh M. Divan G. Koh Y-J. Kim YS. Kauchali S. Marcin C. et al. Global prevalence of autism and other pervasive developmental disorders. Autism Research. 2012;5:160-179. 18. Campbell CA, Davarya S, Elsabbagh M, Madden L, Fombonne E. Prevalence and the Controversy. In: Matson JL, Sturmey P, editors. International Handbook of Autism and Pervasive Developmental Disorders, New York: Springer; 2011 pp. 25-35. 19. Schisterman EF, Cole SR, Platt RW. Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies. Epidemiology. 2009;20(4):488-495. 20. Keyes KM, Susser E, Cheslack-Postava K, Fountain C, Liu K, Bearman PS. Cohort effects explain the increase in autism diagnosis among children born from 1992 to 2003 in California. Int J Epidemiol. 2012;41(2):495-503 21. Spiers N. Cohort effects explain the increase in autism diagnosis among children born from 1992 to 2003 in California [letter]. Int J Epidemiol. 2013;42:1520-1521. 22. King M, Bearman P. Diagnostic change and the increased prevalence of autism. Int J Epidemiol. 2009; 38:1224–1234. 23. Rodgers WL. Estimable Functions of Age, Period, and Cohort Effects. Am Sociol Rev. 1982;47(6):774-787.

818 24. O'Brien RM. Age-Period-Cohort Models. Boca Raton (FL): CRC Press; 2015. 819 25. MacInnis AG. Autism Prevalence Trends by Birth Year and Diagnostic Year: 820 Indicators of Etiologic and Non-Etiologic Factors – an Age Period Cohort Problem 821 [thesis]. Stanford (CA): Stanford University; 2017 DOI: 822 10.13140/RG.2.2.11821.59360. Available from: 823 https://www.researchgate.net/publication/322724736 Thesis Autism Prevalence Tr 824 ends by Birth Year and Diagnostic Year Indicators of Etiologic and Non-825 Etiologic Factors - an Age Period Cohort Problem. 826 26. McKenzie K, Milton M, Smith G, Ouellete-Kuntz H. Systematic Review of the 827 Prevalence and Incidence of Intellectual Disabilities: Current Trends and Issues. Cur 828 Dev Disord Rep. 2016;3:104-115. 829 27. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 830 2009;65(6):591-598. 831 28. MacInnis AG. Time-to-event Prevalence Estimation TTEPE [software]. 2020. OSF 832 repository. Available from: https://doi.org/10.17605/OSF.IO/WPNKU. 833 29. Findley DF. Counterexamples to Parsimony and BIC. Ann Inst Stat Math. 834 1991;43(3):505-514. 835 30. Cox DR. Regression Models and Life Tables. J R Stat Soc Series B Stat Methodol. 836 1972;34(2):187-220. 837 31. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. 838 Hoboken (NJ): Wiley; 2002.

839	32. Hyman SL, Levy SE, Myers SM, AAP COUNCIL ON CHILDREN WITH
840	DISABILITIES, SECTION ON DEVELOPMENTAL AND BEHAVIORAL
841	PEDIATRICS. Identification, Evaluation, and Management of Children With Autism
842	Spectrum Disorder. Pediatrics. 2020;145(1):e20193447. doi: 10.1542/peds.2019-
843	3447.
844	33. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. 3rd ed.
845	Hoboken (NJ): Wiley; 2013.
846	34. Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical
847	methods. Stat Med. 2019;38:2074–2102.